

## **Verastem Inc**

### **CORTELLIS COMPANY DETAILED PIPELINE REPORT**

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 09-Oct-2012

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 8

[Return to Table of Contents](#)

# Verastem Inc

## COMPANY OVERVIEW

Company Name	Verastem Inc
Parent Company Name	Verastem Inc
Website	http://www.verastem.com/
Country	US
Number of Drugs in Active Development	6
Number of Inactive Drugs	0
Number of Patents as Owner	0
Number of Patents as Third Party	0
Number of Deals	5
Key Indications	Cancer
Key Target-based Actions	Beta-catenin inhibitor,Focal adhesion kinase modulator
Key Technologies	Small molecule therapeutic,Natural product

## COMPANY PROFILE

### SUMMARY

Verastem Inc is a biopharmaceutical company focused on discovering and developing drugs targeting cancer stem cells.

### FINANCIAL

In March 2012, the company was added to the Russell 2000 index.

In November 2011, Verastem filed a registration statement for the proposed IPO of its common stock. In January 2012, the Securities and Exchange Commission declared the registration effective, and the company priced the IPO of 5.5 million shares at \$10.00 per share, with underwriters granted a 30-day option to purchase an additional 825,000 shares of common stock to cover overallotments. The shares were to begin trading on the NASDAQ global market on January 27, 2012 under the symbol "VSTM"; in February 2012, underwriters fully exercised their over-allotment option for the purchase of additional common stocks shares. Net proceeds from the IPO were approximately \$56.7 million.

In July 2011, Verastem raised \$32 million from a series B financing.

In November 2010, Verastem raised \$16 million from a series A financing.


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	6	0	6

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 1 Clinical	1
Discovery	5

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### VS-6063

#### VS-6063 SNAPSHOT

Drug Name	VS-6063
Key Synonyms	
Originator Company	Pfizer Inc
Active Companies	Verastem Inc
Inactive Companies	Pfizer Inc
Highest Status	Phase 1 Clinical
Active Indications	Cancer
Target-based Actions	Focal adhesion kinase inhibitor
Other Actions	Anticancer protein kinase inhibitor;Anticancer
Technologies	Small molecule therapeutic;Oral formulation;Capsule formulation
Last Change Date	13-Jul-2012

#### VS-6063 DEVELOPMENT PROFILE

##### SUMMARY

Verastem, under license from Pfizer, is developing VS-6063 (formerly PF-4554878, PF-04554878), the lead from a program of focal adhesion kinase (FAK) inhibitors for the potential treatment of cancer including solid tumors. In December 2008, a phase I trial began ; by July 2012, the trial had been completed ; later that month, phase II study for mesothelioma was expected to be initiated in mid-2013.

Pfizer was previously developing the drug . However, by February 2012, Pfizer had discontinued development and Verastem planned to continue development in July 2012.

Pfizer was also developing PF-562271, a reversible inhibitor of FAK and Pyk2 (FAK2) kinase for the potential oral treatment of cancer.

#### VS-6063 DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Verastem Inc	Cancer	US	Phase 1 Clinical	11-Jul-2012
Pfizer Inc	Cancer	US	Discontinued	28-Feb-2012

[Return to Table of Contents](#)






## VS-6063 DEVELOPMENT STATUS

### HISTORICAL DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfizer Inc	Cancer	US	Phase 1 Clinical	11-Dec-2008
Pfizer Inc	Cancer	US	Discovery	14-Nov-2005

### VS-6063 CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	4
	
Name	Type
PF-941222	Research Code

### VS-6063 DRUG NAMES

Names	Type
PF-941222	Research Code
FAK inhibitors (cancer), Pfizer	
PF-04554878	Research Code
PF-4554878	Research Code
VS-6063	Research Code

### VS-6063 CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All

[Return to Table of Contents](#)

Cancer											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

VS-6063 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Verastem Inc	0	0	1	0	1
Pfizer Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

## salinomycin (cancer), Verastem

### salinomycin (cancer), Verastem SNAPSHOT

Drug Name	salinomycin (cancer), Verastem
Key Synonyms	salinomycin
Originator Company	Verastem Inc
Active Companies	Verastem Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Beta-catenin inhibitor
Other Actions	Anticancer
Technologies	Natural product;Small molecule therapeutic
Last Change Date	18-Jul-2012

### salinomycin (cancer), Verastem DEVELOPMENT PROFILE

#### SUMMARY

Verastem is investigating VS-507, a formulation of salinomycin, from a Wnt/beta-catenin inhibitor program, for the potential treatment of cancer. In March 2012, VS-507 was in IND-enabling toxicology studies. At that time, the company planned to initiate clinical trials with VS-507 over the next 12 to 15 months.

Verastem, in collaboration with Eisai, is also investigating next-generation Wnt inhibitor, for the potential treatment of cancer.

### salinomycin (cancer), Verastem DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Verastem Inc	Cancer	US	Discovery	14-Oct-2009

### salinomycin (cancer), Verastem CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
53003-10-4	2
	
Name	Type
salinomycin	BANN; INN
VS-507	Research Code

### salinomycin (cancer), Verastem DRUG NAMES

Names	Type
salinomycin	INN, BANN
Wnt/beta-catenin program (cancer), Verastem Inc	
salinomycin (cancer), Verastem	
VS-507	Research Code

[Return to Table of Contents](#)

## VS-4718

### VS-4718 SNAPSHOT

Drug Name	VS-4718
Key Synonyms	
Originator Company	Verastem Inc
Active Companies	Verastem Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Focal adhesion kinase modulator
Other Actions	Anticancer
Technologies	Small molecule therapeutic
Last Change Date	13-Jul-2012

### VS-4718 DEVELOPMENT PROFILE

#### SUMMARY

Verastem, under license from an undisclosed company, is investigating VS-4718, the lead from a focal adhesion kinase (FAK) program, including VS-5095 (selective FAK inhibitors), for the potential treatment of cancer,. In June 2012, IND-enabling toxicology studies were initiated. At that time, the company planned to initiate phase I trial in the first quarter of 2013.

### VS-4718 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Verastem Inc	Cancer	US	Discovery	14-Mar-2012

[Return to Table of Contents](#)




VS-4718 DRUG NAMES

Names	Type
focal adhesion kinase program (cancer), Verastem Inc	
VS-4718	Research Code
VS-5095	Research Code
FAK program (cancer), Verastem Inc	

VS-4718 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Verastem Inc	0	0	1	0	1

[Return to Table of Contents](#)



Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

## VS-5584

### VS-5584 SNAPSHOT

Drug Name	VS-5584
Key Synonyms	
Originator Company	S*BIO Pte Ltd
Active Companies	Verastem Inc
Inactive Companies	S*BIO Pte Ltd
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	mTOR inhibitor;Phosphoinositide-3 kinase alpha inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Small molecule therapeutic;Oral formulation
Last Change Date	13-Jul-2012

### VS-5584 DEVELOPMENT PROFILE

#### SUMMARY

Verastem, under license from S\*Bio, is investigating VS-5584 (formerly SB-2343, SB-2312), the lead from a series of orally-available mammalian target of rapamycin/phosphoinositide 3 kinase (mTOR/PI3K) alpha dual inhibitor, for the potential treatment of cancer,. In July 2012, clinical development for advanced solid tumors was expected to be initiated in mid-2013.

The company is also investigating selective mTOR inhibitors for cancer.

### VS-5584 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Verastem Inc	Cancer	US	Discovery	12-Jul-2012
S*BIO Pte Ltd	Cancer	Singapore	Discontinued	12-Jul-2012

### VS-5584 DEVELOPMENT STATUS

#### HISTORICAL DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
S*BIO Pte Ltd	Cancer	Singapore	Discovery	21-Apr-2009

[Return to Table of Contents](#)

## VS-5584 DRUG NAMES

Names	Type
mTOR/PI3K alpha dual inhibitors (cancer), S*BIO	
SB-2312	Research Code
mammalian target of rapamycin/phosphoinositide 3 kinase alpha dual inhibitors (cancer), S*Bio	
SB-2343	Research Code
VS-5584	Research Code

[Return to Table of Contents](#)



## stem cell inhibitors (cancer), Verastem

### stem cell inhibitors (cancer), Verastem SNAPSHOT

Drug Name	stem cell inhibitors (cancer), Verastem
Key Synonyms	
Originator Company	Verastem Inc
Active Companies	Verastem Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	Stem cell inhibitor;Anticancer
Technologies	Small molecule therapeutic
Last Change Date	05-Aug-2011

### stem cell inhibitors (cancer), Verastem DEVELOPMENT PROFILE

#### SUMMARY

Verastem is investigating a series of compounds targeting stem cells, for the potential treatment of cancer including breast cancer. In July 2011, the first candidate from the series was expected to enter clinical development in 2012.

### stem cell inhibitors (cancer), Verastem DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Verastem Inc	Cancer	US	Discovery	16-Nov-2010

### stem cell inhibitors (cancer), Verastem DRUG NAMES

Names	Type
stem cell inhibitors (cancer), Verastem	

[Return to Table of Contents](#)



## next-generation Wnt inhibitors (cancer), Eisai/Verastem

### next-generation Wnt inhibitors (cancer), Eisai/Verastem SNAPSHOT

Drug Name	next-generation Wnt inhibitors (cancer), Eisai/Verastem
Key Synonyms	
Originator Company	Verastem Inc
Active Companies	Eisai Co Ltd;Verastem Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Beta-catenin inhibitor
Other Actions	Anticancer
Technologies	Small molecule therapeutic
Last Change Date	18-Jul-2012

### next-generation Wnt inhibitors (cancer), Eisai/Verastem DEVELOPMENT PROFILE

#### SUMMARY

Verastem, in collaboration with Eisai, is investigating next-generation small molecule Wnt inhibitors, including the analogs of VS-507 (salinomycin), for the potential treatment of cancer. In July 2012, development was ongoing.

### next-generation Wnt inhibitors (cancer), Eisai/Verastem DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Eisai Co Ltd	Cancer	Japan	Discovery	12-Jul-2012
Verastem Inc	Cancer	US	Discovery	12-Jul-2012


### next-generation Wnt inhibitors (cancer), Eisai/Verastem DRUG NAMES

Names	Type
next-generation Wnt inhibitors (cancer), Eisai/Verastem	

[Return to Table of Contents](#)

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Verastem Inc	1	0	0	0	1
Eisai Co Ltd	0	0	1	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)